NYMOX PHARMACEUTICAL CORP (NYMX) Stock Price, Quote, News and Overview
NASDAQ:NYMX - Nasdaq - BSP733981026 - Common Stock - Currency: USD
NYMX Quote, Performance and Key Statistics
0.2
-0.05 (-19.68%)
The current stock price of NYMX is 0.2 USD. In the past month the price decreased by -50.94%. In the past year, price decreased by -51.16%.
NYMX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.17 | 360.64B | ||
| AMGN | AMGEN INC | 15.63 | 166.32B | ||
| GILD | GILEAD SCIENCES INC | 24.08 | 138.34B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1660.86 | 123.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.63 | 77.97B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.11B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.04B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.58B | ||
| NTRA | NATERA INC | N/A | 20.91B | ||
| BIIB | BIOGEN INC | 8.58 | 20.59B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.73 | 15.99B |
Related stock screener links
About NYMX
Company Profile
Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. The company is headquartered in Saint-Laurent, Quebec. The firm is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. Its products include Fexapotide Triflutate, NicAlert and TobacAlert. Fexapotide Triflutate is a protein injectable for benign prostatic hyperplasia (prostate enlargement, BPH) and for low-grade localized prostate cancer. NicAlert is a simple test to determine smoking status. TobacAlert is a home test that provides an on-the-spot determination of a person’s level of exposure to tobacco products, including secondhand smoke. The Company’s lead drug candidate for BPH FT has completed Phase III development in more than 70 clinical centers in the United States. FT has completed a phase II trial in the United States. The company has also developed the AlzheimAlert test. The firm operates in Canada, the United States and Switzerland.
Company Info
NYMOX PHARMACEUTICAL CORP
St. Laurent, 9900 Cavendish Blvd Suite 306
Saint-Laurent QUEBEC H4M 2V2 CA
CEO: Paul Averback
Employees: 3
Company Website: https://nymox.com/
Phone: 18009369669.0
NYMOX PHARMACEUTICAL CORP / NYMX FAQ
What is the stock price of NYMOX PHARMACEUTICAL CORP today?
The current stock price of NYMX is 0.2 USD. The price decreased by -19.68% in the last trading session.
What is the ticker symbol for NYMOX PHARMACEUTICAL CORP stock?
The exchange symbol of NYMOX PHARMACEUTICAL CORP is NYMX and it is listed on the Nasdaq exchange.
On which exchange is NYMX stock listed?
NYMX stock is listed on the Nasdaq exchange.
What is NYMOX PHARMACEUTICAL CORP worth?
NYMOX PHARMACEUTICAL CORP (NYMX) has a market capitalization of 18.10M USD. This makes NYMX a Nano Cap stock.
How many employees does NYMOX PHARMACEUTICAL CORP have?
NYMOX PHARMACEUTICAL CORP (NYMX) currently has 3 employees.
What are the support and resistance levels for NYMOX PHARMACEUTICAL CORP (NYMX) stock?
NYMOX PHARMACEUTICAL CORP (NYMX) has a resistance level at 0.39. Check the full technical report for a detailed analysis of NYMX support and resistance levels.
Should I buy NYMOX PHARMACEUTICAL CORP (NYMX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NYMX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NYMX, evaluating the profitability, health, valuation and growth aspects
- NYMOX PHARMACEUTICAL CORP (NYMX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NYMOX PHARMACEUTICAL CORP (NYMX) Sales and EPS estimates to see what analysts future expectations are.
- NYMOX PHARMACEUTICAL CORP (NYMX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NYMOX PHARMACEUTICAL CORP (NYMX) Insider and Institutional Ownership to learn about the owners and their transactions.
- NYMOX PHARMACEUTICAL CORP (NYMX) Stock Chart to make your own analysis
- NYMOX PHARMACEUTICAL CORP (NYMX) Latest news and press-releases to stay up to date.
Does NYMOX PHARMACEUTICAL CORP (NYMX) stock pay dividends?
NYMX does not pay a dividend.
When does NYMOX PHARMACEUTICAL CORP (NYMX) report earnings?
NYMOX PHARMACEUTICAL CORP (NYMX) will report earnings on 2023-08-15.
What is the Price/Earnings (PE) ratio of NYMOX PHARMACEUTICAL CORP (NYMX)?
NYMOX PHARMACEUTICAL CORP (NYMX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.03).
NYMX Technical Analysis
NYMX Financial Highlights
Over the last trailing twelve months NYMX reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS increased by 82.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |